From Monkeypox to new COVID variants, the global demand for vaccines is on the rise. What are the vaccine makers most popular amongst the investor community? The list’s performance is calculated on an equally weighted method.
This list has performed -24.40% over the past year. By comparison, NASDAQ Singapore SGD Index is 1.73% over the same period. The beta of this list, which is a measure of volatility, is Moderately Low at 0.82. List Beta is calculated using an equally weighted average beta of the securities within this list. This list includes 90.00% of Healthcare stocks, 10.00% of Financials stocks.
List performance is calculated using an equal-weight methodology. This list is generated by scanning the web and using our algorithms to surface potentially relevant securities to the topic. The list is intended to be educational and includes securities that may be suitable for a watchlist. It is not intended for investment or trading purposes. Microsoft does not recommend using the data and information provided as the basis for making any investment decision.
PFIZER INC.
PFE. Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.
Pfizer Inc. is -10.18% over the past month and -13.49% over the past year, underperforming the NASDAQ Singapore SGD Index by -8.65% over the past month and -15.21% over the past year.
JOHNSON & JOHNSON
JNJ. Johnson & Johnson is a diversified healthcare products company. The Company is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer Health, Pharmaceutical and MedTech. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The MedTech segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.
Johnson & Johnson. is -8.76% over the past month and -5.36% over the past year, underperforming the NASDAQ Singapore SGD Index by -7.23% over the past month and -7.09% over the past year.
MODERNA, INC.
MRNA. Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.
Moderna Inc. is -10.26% over the past month and +13.50% over the past year, underperforming the NASDAQ Singapore SGD Index by -8.73% over the past month and +11.78% over the past year.
MERCK & CO., INC.
MRK. Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species.
Merck & Co Inc. is -5.13% over the past month and +37.90% over the past year, underperforming the NASDAQ Singapore SGD Index by -3.61% over the past month and +36.18% over the past year.
NOVAVAX, INC.
NVAX. Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).
Novavax Inc. is -18.71% over the past month and -88.46% over the past year, underperforming the NASDAQ Singapore SGD Index by -17.19% over the past month and -90.18% over the past year.